Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M
Source: SeekingAlpha
2025-03-12 06:53:54 ET
More on Ionis Pharmaceuticals, Ono Pharmaceutical, etc.
- Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript
- Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
- Ionis Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation
- Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches
- Ionis posts Q4 beat as revenue base widens
Read the full article on Seeking Alpha
For further details see:
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M
Ono Pharmaceutical Co Ltd ADR
NASDAQ: OPHLY
OPHLY Trading
-0.94% G/L:
$4.9845 Last:
88,072 Volume:
$4.98 Open:
